EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.

View source ↗

Summary

EMA authorised Padcev (enfortumab vedotin) for conditions within transitional cell carcinoma and urologic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Transitional Cell
• Urogenic Neoplasms

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Transitional Cell;Urologic Neoplasms. MAH: Astellas Pharma Europe B.V.. Decision date: 19/06/2026